Where RMR1 landed: 1,000 mice, treatment from 18 months, four interventions (rapamycin, senolytics, telomerase gene therapy, haematopoietic stem cell transplant); the last mouse died on 12 February 2025. LEVF's own December 2025 update says the interventions were additive but that four were insufficient to reach the 12-month target, with unexpected sex differences, and that RMR2 (at least eight interventions, with the repair treatments repeated) is likely to start its main phase around mid-2026 with significant results in 2028. For scale, 12 extra months in a 30-month strain is a 40% gain; the best replicated single-drug effect in the NIA Interventions Testing Program is 23 to 26% (rapamycin), and rapamycin plus acarbose is the only combination that has beaten rapamycin alone there. The next species up, dogs, has its first placebo-controlled lifespan trials running now; the TRIAD record with sources (mine): https://w0lph.github.io/k9/trials/triad-rapamycin.html

Test of Rapamycin in Aging Dogs (TRIAD): canine aging trial registry record

TRIAD is a parallel-group, double-masked, randomized, placebo-controlled, multicenter trial that will test whether rapamycin prolongs lifespan and improves healthspan metrics in healthy, middle-aged, large-breed dogs recruited from Dog Aging Project participants. The hypothesis is that a one-year co

How will you know the answer to this in 2 days? Is it being announced somewhere?

How are you judging success?

@IsaacKing produces at least ONE mouse in any cohort that exceeds the maximum lifespan of non-genetically modified "normal" B6 mice